Clinical Trial Update: Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing the efficacy of idelalisib plus obinutuzumab in relapsed/refractory Waldenström's macroglobulinemia has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Idelalisib (idelalisib)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: French Innovative Leukemia Organisation | Conditions: Waldenstrom Macroglobulinemia | Phase 2 | Status: COMPLETED